Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRF | P10586 | 9/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 9/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.51 |
| ▸ | BCHE | P06276 | 8/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1659911 | 0.91 | PTPRF (0.60) | PTPRFPTPN2PTPN1BCHEADORA2A | |
| SCHEMBL15240243 | 0.91 | PTPRF (0.60) | PTPRFPTPN2PTPN1BCHEADORA2A | |
| SCHEMBL1659912 | 0.91 | PTPRF (0.60) | PTPRFPTPN2PTPN1BCHEADORA2A | |
| SCHEMBL1659758 | 0.88 | PTPRF (0.50) | PTPRFPTPN2PTPN1BCHEADORA2A | |
| SCHEMBL1657084 | 0.85 | PTPRF (0.47) | PTPRFPTPN2PTPN1BCHEADORA2A | |
| SCHEMBL12797573 | 0.85 | PTPRF (0.47) | PTPRFPTPN2PTPN1BCHEADORA2A | |
| SCHEMBL1658006 | 0.82 | PTPRF (0.53) | PTPRFPTPN2PTPN1BCHEADORA2A | |
| SCHEMBL16418298 | 0.82 | PTPRF (0.52) | PTPRFPTPN2PTPN1BCHEADORA2A | |
| SCHEMBL12798895 | 0.82 | PTPRF (0.52) | PTPRFPTPN2PTPN1BCHEADORA2A | |
| SCHEMBL1657894 | 0.80 | PTPRF (0.59) | PTPRFPTPN2PTPN1BCHENOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082192-A1 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | claimed |
| US-8946451-B2 | Lipoic acid acylated salicylate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946451-B2 | Lipoic acid acylated salicylate derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| WO-2011044138-A1 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082192-A1 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082192-A1 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES | ACACA, ACAT2, ACACB | PTPRF 1458/4885PTPN2 853/4885PTPN1 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.